French chemicals company Rhodia has effectively written off the
value of its troubled Rhodia Pharma Solutions division in its
second quarter accounts, giving it a book value of zero.
Charles River Laboratories saw a double digit boost in fiscal
second quarter revenues with a leap in operating earnings, helped
by its acquisition of Inveresk Research Group, and also to
continuing strong demand for research models...
Swiss chemicals company Clariant saw its operating profit decline
by nearly a third as higher raw material costs took their toll,
although net profit rose 18 per cent, boosted by lower
restructuring charges compared to the same period...
Italy's Recordati has reported flat turnover but a rise in
operating income in 2004, while its pharmaceutical chemicals
business managed to return to profit, reports Phil Taylor.
Swiss chemicals and contract manufacturing concern Lonza reported a
decline in sales but net profit up by more than half in 2004,
although earnings came in at the low end of analysts' forecasts.
Cardinal Health reported its long-delayed fourth-quarter financial
results yesterday, revealing a hike in profit and revenues for the
three months to end June, but lowered guidance for the first half
of this fiscal year.
Dutch chemicals and drugs group Akzo Nobel saw its net income
accelerate in the third quarter of this year, to the surprise of
analysts and investors, and helped by cost reductions and a big
gain from the divestment of its coatings...
Filtration specialist Pall has seen its second quarter sales and
earnings held back by weak demand in the biopharmaceuticals
industry, particularly in Europe.
LION bioscience has delayed the publication of its third-quarter
results after a change in its accounting procedures that will see
licence revenues spread across the term of the contracts, instead
of booked in the quarter they are...
Pharmaceutical, chemical and coatings company Akzo Nobel reported a
9 per cent slide in net income in 2003 but said the result was
better than expected given the difficult operating environment last
year.
Agilent returns to profit for the first time in two years in the
fourth quarter ended October 31, as cost-cutting compensated for a
modest decline in revenues.
Kyowa Hakko reaps the benefit of a strong performance in its
biochemicals business, particularly for amino acids, with a 61.5
per cent rise in operating profit.
Cardinal Health posted higher earnings in the first quarter of
fiscal 2004, on the back of increased demand in its prescription
drug wholesale business but also some impressive gains at its
pharmaceutical technologies activities....
Pall has reported a 10 per cent rise in sales to $471 million
(€430m) in the fourth quarter, boosted by currencies and the
recently-acquired FSG operations.
Just over a year after acquiring the FSG business from Vivendi for
$360 million (€307m), Pall Corp has reported a healthy hike in
fiscal third-quarter sales and profits and once again raised its
earnings forecast for 2003.
The global economic downturn marked 2003 first quarter results for
Dutch based life science company DSM but strong autonomous volume
growth boosted figures to higher than 2002.
Applied Biosystems group, the world's number one maker of
gene-analysing equipment, warned on Tuesday that it would report
lower-than-expected fiscal third-quarter revenue and earnings due
to deteriorating business conditions.
